H.C. Wainwright analyst Sean Lee lowered the firm’s price target on Plus Therapeutics (PSTV) to $1 from $2 and keeps a Buy rating on the shares. The firm cites diluting from the company’s recent equity offering for the target cut. It sees a “catalyst-rich” 2026 for Plus Therapeutics.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV: